The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects
- collapse A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD8683 After Single Ascending Doses Administered Via Turbuhaler in Healthy Subjects
- collapse The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
- collapse An Open-Label, Single Center An Open, Partly Randomised, Four-way Cross-over Study in Healthy Subjects and in Patients with Mild Allergic Asthma to Investigate the Bioavailability and Basic Pharmacokinetics of a Single Dose of AZD5423 when Administered Intravenously, Orally, Inhaled via SPIRA Nebuliser or Inhaled via I-neb® AAD Systems
- collapse An open-label, partially randomized, 5-way crossover study in healthy volunteers to assess the relative bioavailability of 100 and 150 mg fostamatinib tablets compared with 50 mg fostamatinib tablets
- collapse Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
- collapse Efficacy and Safety Study or Fostamatinib Disodium Tablets to Treat B-cell Lymphoma
- collapse AZD2115 Single Ascending Dose Study
- collapse An Open, Non-controlled, Non-randomised, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD8848 Administered Intranasally to Male and Female Butyrylcholinesterase Deficient Subjects and to Sex and Age Matched Controls
- collapse An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects when Administered Alone and in Combination with Fostamatinib 100 mg Twice Daily
